Foundayo Efficacy Data Reinforces Product, but Not the Investment Case

What happened

Eli Lilly announced an indirect treatment comparison showing Foundayo (orforglipron) 17.2 mg achieved 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks in adults with type 2 diabetes, building on earlier ACHIEVE-3 head-to-head results against the 14 mg dose. While the data support Foundayo's efficacy profile, the comparison is indirect rather than a direct head-to-head against the higher semaglutide dose, limiting its evidentiary weight. The positive efficacy signal does not address the core concerns flagged in our DeepValue report: price erosion, uncertain Medicare Bridge uptake, and Foundayo's early channel mix heavily skewed toward LillyDirect and telehealth. The stock remains a WAIT as the investment case hinges on stabilization of realized prices and evidence that oral GLP-1 demand normalizes beyond direct channels. Today's announcement is unlikely to shift the valuation debate meaningfully.

Implication

For investors, the efficacy data reinforce Foundayo's competitive positioning but do not resolve the key risks that underpin the WAIT rating. The market already prices in oral obesity expansion, so incremental efficacy comparisons against semaglutide are unlikely to move the needle. The critical watch items remain U.S. realized-price stability for Mounjaro and Zepbound, tangible Medicare Bridge uptake, and Foundayo's shift from direct-to-consumer channels to normal retail and payer workflows. Until quarterly filings provide hard evidence on those fronts, the valuation at 39.8x earnings leaves little margin for error. A disciplined approach suggests waiting for more durable economic proof before increasing exposure.

Thesis delta

The news provides additional efficacy support for Foundayo but does not address the central concerns of pricing pressure, channel normalization, or Medicare access execution. Therefore, there is no material change to the investment thesis. The WAIT rating remains appropriate.